FDA
-
-
-
-
-
-
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
-
-
-
-
-
-
Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update
-
-
-
-
-
-
-
Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada
-
-
-
-
-
-
-
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
-
-
-
-
-
-
-
Chimerix to Present at B. Riley Virtual Oncology Conference
-
-
-
-
-
-
-
Chimerix Announces Upcoming Presentations at the Society for Neuro-Oncology Annual Meeting 2021
-
-
-
-
-
-
-
Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

